India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure.

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss ...

Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current ...